Arbutus Biopharma Corporation Common Stock (ABUS)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earning power bought below intrinsic value. Arbutus is not that today. It is a clinical-stage biopharma with 19 employees, developing hepatitis B candidates Imdusiran and AB-101. The science may be optionality, but I see no proven commercial moat. Reported results are erratic. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $179.1 million and net income was $169.7 million, or diluted EPS of $0.87. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue fell to $1.0 million and net loss was $5.1 million, or diluted EPS of -$0.03. Full-year fiscal 2025 had revenue of $14.1 million and a net loss of $33.5 million, after losses of $69.9 million in fiscal 2024 and $72.8 million in fiscal 2023. That is why FairStock assigns no Lynch category: losses in each of the last four years. The balance sheet is conservative—debt-to-equity of 0.01 and Altman Z-Score of 26.81—but trailing free cash flow is -$24.6 million. At the close on 2026-10-13, the price was $4.11. FairStock's P/E is 5.20, P/B 3.14, EV/EBITDA 5.19, ROE 89.58%, and ROCE 48.84%, but those are distorted by the fiscal Q1 2026 windfall. Its Graham Number is $4.83, offering only a 14.91% margin of safety. Piotroski F-Score is 2/9. Price looks close to fair, not compelling, and the business remains speculative.

In plain English: Arbutus Biopharma is a small biotechnology company working on treatments for chronic hepatitis B. It is not a profitable business yet: it lost money in each of the last four years, and in the latest reported quarter revenue was only $1.0 million with a $5.1 million loss. At $4.11 a share, the price looks roughly near its accounting-based fair value, but the continuing losses and uneven results make the business look weak and the price hard to call cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer